The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled
nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a
supporting and safe therapy and to evaluate the pharmacokinetics of bosentan and its
metabolites.